Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGonzález, Sara
dc.contributor.authorMunté, Elisabet
dc.contributor.authorFeliubadaló, Lidia
dc.contributor.authordel Valle, Jesús
dc.contributor.authorRamos-Muntada, Mireia
dc.contributor.authorBalmaña, Judith
dc.date.accessioned2024-08-21T08:09:17Z
dc.date.available2024-08-21T08:09:17Z
dc.date.issued2024-08
dc.identifier.citationMunté E, Feliubadaló L, Del Valle J, González S, Ramos-Muntada M, Balmaña J, et al. Open-source bioinformatic pipeline to improve PMS2 genetic testing using short-read NGS data. J Mol Diagnostics. 2024 Aug;26(8):727–38.
dc.identifier.issn1943-7811
dc.identifier.urihttps://hdl.handle.net/11351/11852
dc.descriptionBioinformatics; Open-Source; Genetic Testing
dc.description.abstractThe molecular diagnosis of mismatch repair–deficient cancer syndromes is hampered by difficulties in sequencing the PMS2 gene, mainly owing to the PMS2CL pseudogene. Next-generation sequencing short reads cannot be mapped unambiguously by standard pipelines, compromising variant calling accuracy. This study aimed to provide a refined bioinformatic pipeline for PMS2 mutational analysis and explore PMS2 germline pathogenic variant prevalence in an unselected hereditary cancer (HC) cohort. PMS2 mutational analysis was optimized using two cohorts: 192 unselected HC patients for assessing the allelic ratio of paralogous sequence variants, and 13 samples enriched with PMS2 (likely) pathogenic variants screened previously by long-range genomic DNA PCR amplification. Reads were forced to align with the PMS2 reference sequence, except those corresponding to exon 11, where only those intersecting gene-specific invariant positions were considered. Afterward, the refined pipeline's accuracy was validated in a cohort of 40 patients and used to screen 5619 HC patients. Compared with our routine diagnostic pipeline, the PMS2_vaR pipeline showed increased technical sensitivity (0.853 to 0.956, respectively) in the validation cohort, identifying all previously PMS2 pathogenic variants found by long-range genomic DNA PCR amplification. Fifteen HC cohort samples carried a pathogenic PMS2 variant (15 of 5619; 0.285%), doubling the estimated prevalence in the general population. The refined open-source approach improved PMS2 mutational analysis accuracy, allowing its inclusion in the routine next-generation sequencing pipeline streamlining PMS2 screening.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesThe Journal of Molecular Diagnostics;26(8)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCàncer - Aspectes genètics
dc.subjectCàncer - Diagnòstic
dc.subjectCromosomes humans - Anomalies - Diagnòstic
dc.subjectBioinformàtica
dc.subject.meshNeoplasms
dc.subject.meshGenetic Testing
dc.subject.meshGerm-Line Mutation
dc.subject.meshComputational Biology
dc.titleOpen-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.jmoldx.2024.05.005
dc.subject.decsneoplasias
dc.subject.decspruebas genéticas
dc.subject.decsmutación de la línea germinal
dc.subject.decsbiología computacional
dc.relation.publishversionhttps://doi.org/10.1016/j.jmoldx.2024.05.005
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Munté E] Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain. Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d’Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain. [Feliubadaló L, Del Valle J] Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain. Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d’Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain. Ciber Oncología, Instituto Salud Carlos III, Madrid, Spain. [González S] Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain. Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d’Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain. [Ramos-Muntada M] Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d’Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain. Ciber Oncología, Instituto Salud Carlos III, Madrid, Spain. [Balmaña J] High Risk and Cancer Prevention Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid38851388
dc.identifier.wos001279922100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record